Clinical Trials Logo

Diabetic Macular Edema clinical trials

View clinical trials related to Diabetic Macular Edema.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 3

NCT ID: NCT01790945 Not yet recruiting - Clinical trials for Diabetic Macular Edema

Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography

DIVER
Start date: February 2013
Phase: N/A
Study type: Observational

The purpose of this study is explore if a partnership and screening program put in place between a busy retina practice and their referring diabetes care offices can improve diabetic retinopathy and diabetic macular edema diagnosis, care and overall diabetes control in patients with diabetic eye disease.

NCT ID: NCT01523314 Not yet recruiting - Clinical trials for Diabetic Macular Edema

Topical Dexamethasone - Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema

DECEDE
Start date: March 2012
Phase: Phase 2/Phase 3
Study type: Interventional

The research group has developed new ocular drug delivery technology based on cyclodextrin nanoparticles (NP). The investigators plan to develop and test this technology to help treat diabetic macular edema (DME). An important step in research was the invention of cyclodextrin nanoparticles, which has just received a US patent. The investigators pre-clinical and clinical work has demonstrated the investigators eye drop suspension with cyclodextrin nano-particles to be superior to conventional eye drops. They increase drug absorbance into the eye and decrease systematic distribution of the drug, hence reducing side effects. Cyclodextrin nanoparticle eye drops deliver drugs to the posterior part of the eye, thus solving one of the biggest obstacles in ocular pharmacology.

NCT ID: NCT01107132 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus

Start date: May 2010
Phase: N/A
Study type: Observational

In Type 2 Diabetes mellitus patients we will: 1. quantify vasculopathy and blood-retinal barrier (BRB) leakage 2. measure blood-brain barrier (BBB) permeability and neuroanatomical changes 3. correlate BRB pathology with BBB breakdown, inflammatory markers and neuropsychiatric sequela